NEW THERAPEUTIC AGENTS FOR GALLSTONE DISSOLUTION

胆结石的主要治疗方法是手术切除。利率为1% 死亡率和巨额住院费用，寻求更少的 昂贵和安全的胆结石溶解治疗是有必要的。它 研究表明，胆结石主要由胆固醇和胆固醇组成。 它的形成是由于超过了 胆汁中的胆固醇。因此，有人建议用口述的方式 用适当的胆汁酸治疗可以起到溶解胆结石的作用。 代理，从而消除了手术的需要。这个项目的目标是 是为了证明头部基团的短链类似物被修饰 磷脂酰胆碱具有更好的增溶性能，与 其他潜在的胆固醇增溶剂与 它们溶解先前存在的胆固醇晶体的速度。应该 第一阶段研究成功，第二阶段研究将集中在 修饰磷脂酰胆碱口服给药能力的研究 动物模型中的肠-肝循环。第三阶段测试将 包括初步的人体研究。

The primary treatment for gallstones is surgical removal. With a 1% mortality rate and substantial hospitalization costs, a search for less expensive and safer treatment for gallstone dissolution is warranted. It has been shown that gallstones consist primarily of cholesterol and their formation is a consequence of exceeding the solubility limits of cholesterol in the bile. As a result, it has been proposed that oral treatment with suitable bile acids may act as a gallstone dissolving agents, thereby eliminating the need for surgery. The goal of this project is to demonstrate that short chain analogs of head group modified phosphatidylcholines have superior solubilizing properties, compared with other potential cholesterol solubilizing agents relative to the amount and speed at which they can dissolve pre-existing cholesterol crystals. Should Phase I studies be successful, then Phase II studies would concentrate on the ability of oral intake of modified phosphatidylcholines to enter into the enterohepatic circulation in animal models. Phase III testing would consist of preliminary human studies.